Legend Biotech Corp
Legend Biotech Corp is listed today as Legend Biotech Corporation: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2023 | $200 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Mar 2020 | $150 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Legend Biotech Corp chose not to state its revenue in its newest notice of a funding round (Apr 2023).
SEC Form D · Apr 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2023
That is all the official record says: Legend Biotech Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Legend Biotech Corp are on record.
Investors#
No investor of Legend Biotech Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.
Largest shareholders today
Institutions holding Legend Biotech Corporation shares, as of Sep 30, 2026.
- FMR LLC$481 M11.70%
- Kynam Capital Management, LP$182 M4.43%
- Hhlr Advisors, LTD.$166 M4.04%
- Deerfield Management Company, L.P.$162 M3.94%
- Montanova Capital, LLC$124 M3.01%
- Westfield Capital Management Co LP$102 M2.49%
- BlackRock, Inc.$101 M2.46%
- State Street Corp$32 M0.78%
- Point72 Asset Management, L.P.$32 M0.78%
- Elmind Capital, LP$31 M0.76%
- Two Sigma Investments, LP$30 M0.74%
- Morgan Stanley$30 M0.73%
- Renaissance Technologies LLC$24 M0.59%
- AIHC Capital Management Ltd$24 M0.57%
- Balyasny Asset Management L.P.$23 M0.57%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Lori Macomber | Executive officer | Apr 2023 |
| Ying Huang, Ph.D. | Executive officer | Apr 2023 |
| Yuan Xu, Ph.D. | Executive officer | Apr 2020 |
| Corazon D. Sanders, Ph.D. | Director | Apr 2023 |
| Darren Xiaohui Ji, M.D., Ph.D. | Director | Apr 2023 |
| Fangliang Zhang, Ph.D. | Director | Apr 2023 |
| Li Wai Man Mao, MD | Director | Apr 2023 |
| Li Zhu, Ph.D. | Director | Apr 2023 |
| Patrick Wai Man Casey, Ph.D. | Director | Apr 2023 |
| Philip Wai Man Yau, CPA | Director | Apr 2023 |
| Tomas Wai Man Heyman | Director | Apr 2023 |
| Ye Wang, M.S. | Director | Apr 2023 |
| Ying Huang, Ph.D. | Director | Apr 2023 |
| Yuan Xu, Ph.D. | Director | Apr 2020 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.